S0360090
(RS)-Selegiline hydrochloride
European Pharmacopoeia (EP) Reference Standard
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C13H17N · HCl
Numéro CAS:
Poids moléculaire :
223.74
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24
Produits recommandés
Qualité
pharmaceutical primary standard
Famille d'API
selegiline
Fabricant/nom de marque
EDQM
Application(s)
pharmaceutical (small molecule)
Format
neat
Température de stockage
2-8°C
InChI
1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H
Clé InChI
IYETZZCWLLUHIJ-UHFFFAOYSA-N
Description générale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
(RS)-Selegiline hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Conditionnement
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Autres remarques
Sales restrictions may apply.
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Choose from one of the most recent versions:
Certificats d'analyse (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Tamás Tábi et al.
Expert opinion on drug metabolism & toxicology, 9(5), 629-636 (2013-03-20)
Parkinson's disease affects a growing number of people. Its major treatment, levodopa therapy, however suffers from response fluctuations in the advanced phase of the disease. Adjunctive therapies have thus gained significant importance. The selective monoamine oxidase B inhibitor, selegiline
Johanna E Kowalko et al.
Current biology : CB, 23(19), 1874-1883 (2013-09-17)
Surface populations of Astyanax mexicanus, living in rivers like their common ancestors, school, while several, independently derived cave populations of the same species have lost schooling behavior. We quantify schooling behavior in individual A. mexicanus and identify quantitative trait loci (QTL)
[Primary prevention with enhancer substances for a longer and healthier life].
Ildikó Miklya
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 15(2), 58-59 (2013-07-03)
José A G Agúndez et al.
Expert opinion on drug metabolism & toxicology, 9(7), 859-874 (2013-04-10)
The development of pharmacogenetic-based clinical practice guidelines for the use of anti-Parkinson's disease drugs requires, as a pre-requisite, the identification and validation of genetic biomarkers. These biomarkers are then used as surrogate endpoints. This review analyzes potential genetic biomarkers which
Maria J Matos et al.
European journal of medicinal chemistry, 63, 151-161 (2013-03-12)
A series of (coumarin-3-yl)carbamates was synthesized and evaluated in vitro as monoamine oxidase (MAO-A and MAO-B) inhibitors. Most of the new compounds selectively inhibited MAO-B isoenzyme with IC50 values in the micro or nanoMolar ranges. Since these compounds must achieve the
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique